Clinical Trials Registry - India (CTRI)

What it is

Clinical Trials Registry - India (CTRI), launched in 2007, is India's free public registry for clinical studies conducted in the country. It is an online database created to improve transparency in research by making key trial details publicly available before or during a study. For patients and families, the most important point is that a CTRI record shows that a study has been formally registered, but registration alone does not prove that a treatment is effective, safe, or right for you.

CTRI was launched on 20 July 2007 and is part of the World Health Organization's International Clinical Trials Registry Platform network. It was initially voluntary, but prospective registration became mandatory in India for regulatory studies and, from 1 April 2018, CTRI moved to mandatory prospective registration of all studies submitted to it. The registry includes interventional and observational studies, postgraduate thesis research, bioavailability and bioequivalence studies, and other health research involving human participants.

A typical CTRI entry includes the trial title, health condition, intervention, study design, sponsor, sites, ethics approval status, inclusion and exclusion criteria, and planned outcomes. Each registered study receives a unique CTRI number, which helps readers, clinicians, ethics committees, journals, and regulators identify the study.

CTRI feature	What it means for readers
Public registration	Basic study details can be searched online
Unique CTRI number	Helps identify the exact study
Prospective registration preferred	Trial should ideally be registered before enrolling the first participant
Includes many study types	Not limited to drug trials or cancer trials
Transparency tool	Useful for checking whether a study exists and what it planned to do

For cancer care in India, CTRI can help patients find whether a hospital or research group is running a study in a specific cancer type. It can also help you compare what a trial planned to study with what later appears in publications.

How it works

CTRI works as a structured public record system. Investigators or sponsors submit study details through the registry, and the record is reviewed for completeness before being made public. The purpose is not to approve the science or certify quality in the way a regulator or ethics committee does. Instead, the registry creates a time-stamped public record of what the study intended to do.

This matters because trial registration can reduce selective reporting. If outcomes are listed in advance, readers can later check whether published papers reported the same outcomes or changed them after results were known. Registration also makes it easier to identify unpublished or discontinued studies, which is important when doctors and guideline groups assess the full evidence on a treatment.

CTRI is linked to broader international efforts to improve research transparency. WHO has long supported public registration of clinical trials, and many journals require trial registration before publication. In India, CTRI became the main national platform for this purpose.

In practical terms, a CTRI record can help answer questions such as:

1. Is this study actually registered?
2. What treatment or procedure is being tested?
3. Who is sponsoring it?
4. Where is it being conducted?
5. Who may be eligible to join?
6. What outcomes is the study measuring?

Evidence and uses

CTRI is not a treatment, test, or medicine. Its value is in research transparency, accountability, and public access to trial information. Articles reviewing CTRI describe it as a major step in improving openness in Indian clinical research.

For patients, the main uses are:

• checking whether a trial mentioned by a hospital or advertisement is formally registered
• finding basic information about eligibility and study sites
• understanding whether a study is interventional or observational
• noting whether the trial was registered prospectively or retrospectively
• using the CTRI number to search for related publications

For researchers and journals, CTRI helps track protocol details and supports better reporting standards. For ethics committees and policymakers, it offers a way to monitor the clinical research environment in India.

That said, CTRI has limits. A registered trial may still have design problems, may recruit slowly, may stop early, or may never publish full results. Some records may be incomplete, updated late, or registered retrospectively. Audits after the 2018 policy change suggest prospective registration improved, but retrospective registration and data-quality issues have not disappeared completely.

For cancer patients, this distinction is important. A CTRI listing can be a useful starting point when exploring clinical trial options in India, especially at academic centres and large oncology hospitals. But decisions about joining a trial should still depend on the trial phase, treatment rationale, eligibility criteria, possible benefits, side effects, costs, travel burden, and the quality of informed consent.

When to see a clinician

If you find a cancer study on CTRI that seems relevant, discuss it with your oncologist rather than contacting the study team on your own as your only source of advice. Your doctor can help you judge whether the trial phase, treatment goals, and eligibility criteria fit your diagnosis, stage, prior treatments, and overall health.

Ask specific questions, such as:

• Is this trial intended for my exact cancer type and stage?
• Is it a standard-treatment comparison, an add-on study, or an early-phase trial?
• What tests, hospital visits, and costs are involved?
• Could joining delay standard treatment?
• What are the likely side effects and unknowns?

You should also ask whether the study has ethics committee approval at the site where you may enroll and whether the informed consent document clearly explains compensation, injury management, and contact details. If anything in the registry entry and the consent form does not match, ask for clarification.

Limitations and open questions

CTRI improves transparency, but it is not a guarantee of scientific quality, participant protection, or treatment benefit. A registry entry is only as useful as the accuracy and completeness of the information entered and updated.

Several open issues remain. One is the quality and timeliness of data updates, including recruitment status and final results. Another is how often registered outcomes match published outcomes. A further question is how easy the registry is for patients to use when searching for relevant studies, especially in complex fields such as oncology.

Evidence from audits and reviews suggests CTRI has strengthened India's research reporting culture, especially after mandatory prospective registration rules were tightened. Even so, evidence on the consistency of compliance across all study types is still evolving. Patients should use CTRI as a transparency and discovery tool, not as proof that a trial is trustworthy or suitable.

If you are considering a trial in India, the safest approach is to use CTRI together with advice from your treating clinician, the hospital research office, the participant information sheet, and published peer-reviewed evidence where available.